Journal Article10.1345/APH.18190
Treatment of Malignant Melanoma
18
TL;DR: To date, dacarbazine still appears to be the treatment of first choice in metastatic melanoma, outside of a clinical trial, and the combination of chemotherapy with interferon alfa-2b or interfero-2a enhances toxicity without a significant survival advantage.
read more
Abstract: OBJECTIVE:To review the current treatments for cutaneous melanoma and discuss treatment approaches for each patient population.DATA SOURCES:MEDLINE and IOWA database search from January 1990 to December 1998.DATA EXTRACTION:Clinical trials and review articles were selected and classified to answer questions considered of clinical relevance.RESULTS:Patients with stage I, II, and III melanoma should undergo excision after biopsy. In patients with stage IV melanoma, surgical excision of metastatic melanoma is not considered curative but can provide palliation and improve quality of life. Therapeutic lymph node dissection should be performed in patients with melanoma in stages III and IV once pathologic confirmation is obtained. Patients at high risk for recurrence or metastasis may also be considered for elective node dissection. Adjuvant therapy after surgery excision is not a standard of care in patients with stage I and IIa melanoma. In patients with stage IIb and III melanoma, the best results have been ...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy.
Lucie Heinzerling,Günter Burg,Reinhard Dummer,T Maier,Patrick A. Oberholzer,Jan Schultz,Lina Elzaouk,Jovan Pavlovic,Karin Moelling +8 more
TL;DR: Results show that intratumoral injection of DNA produced some beneficial clinical effect against various human cancers, and patients, in particular the clinical and local responders, exhibited an antigen-specific immune response against MAGE-1 and MART-1, which in some cases preexisted.
164
Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses.
Lucie Heinzerling,Karsten Feige,Stefan Rieder,Margarete K. Akens,Reinhard Dummer,Gerald Stranzinger,Karin Moelling +6 more
TL;DR: The results demonstrate the effectiveness and safety of interleukin 12 encoding plasmid DNA therapy against established metastatic disease in a large animal model and serve as a basis for a clinical trial.
98
Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Igor N. Ivashko,Jill M. Kolesar +1 more
TL;DR: Pembrolizumab and nivolumab monotherapies are effective therapies in ipilimumab-refractory metastatic melanoma and present an overall favorable toxicity profile.
86
Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
Ketil André Camilio,Gerd Berge,Chandra Sekhar Ravuri,Øystein Rekdal,Baldur Sveinbjørnsson,Baldur Sveinbjørnsson +5 more
TL;DR: In vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice indicate that intratumoral treatment with L TX-315 can provide local tumor control followed by protective immune responses and has potential as a new immunotherapeutic agent.
References
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
John M. Kirkwood,Myla Hunt Strawderman,Marc S. Ernstoff,Thomas J. Smith,Ernest C. Borden,Ronald H. Blum +5 more
TL;DR: IFN alpha-2b is the first agent to show a significant benefit in relapse-free and overall survival of high-risk melanoma patients in a randomized controlled trial.
2.1K
Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2
Steven A. Rosenberg,James Chih-Hsin Yang,Suzanne L. Topalian,Douglas J. Schwartzentruber,Jeffrey S. Weber,David R. Parkinson,Claudia A. Seipp,Jan Einhorn,Donald E. White +8 more
TL;DR: Because IL-2 does not have a direct effect on cancer cells but rather mediates its antitumor activity by altering host immune reactions, these data represent the best available evidence that immunologic therapy for cancer can be effective in selected patients.
1.1K
Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study.
Franklin H. Sim,William F. Taylor,Douglas J. Pritchard,Edward H. Soule +3 more
- 01 Sep 1986
TL;DR: No significant difference was found among the three treatment groups with respect to survival or metastasis-free survival, and multifactorial analysis indicated that the level of invasion and the thickness of the lesion were the most important prognostic factors.
408
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.
Edward T. Creagan,Robert J. Dalton,D. L. Ahmann,Sin-Ho Jung,Roscoe F. Morton,R. M. Langdon,John W. Kugler,L. J. Rodrigue +7 more
TL;DR: Findings indicate trends that suggest a possible benefit for selected patients with high-risk malignant melanoma, which will require further study in a larger patient population for confirmation.
243